Search

Your search keyword '"Serina-treonina quinasas TOR"' showing total 4 results
Start Over Descriptor "Serina-treonina quinasas TOR" Topic cancer
4 results on '"Serina-treonina quinasas TOR"'

1. La vía canónica PI3K/AKT/mTOR y sus alteraciones en cáncer.

Author

F., Aldecoa and J., Ávila

Abstract

The PI3K/AKT/mTOR pathway is involved in multiple cellular processes which are essential for the cells. Some genetic mutations of the components of this pathway have been associated with various human diseases, the most important of which are breast, thyroid and endometrium carcinomas; glioblastoma multiforme; prostate cancer and lymphomas. The PI3K/AKT/mTOR canonical pathway has been extensively studied in recent years. However, as the complexity of its main components and their correlation with the components of other pathways are increasing, it is important to update from time to time the available information to understand this mechanism. Furthermore, many trials have been conducted with selective medicines aimed to look for a more intelligent treatment for diseases associated with alterations in this pathway. Therefore, we review this transduction pathway to take a close look at its functioning and alterations, and to list some promising molecules for future treatments. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

2. The PI3K/AKT/mTOR canonical pathway and its alterations in cancer

Author

FRANKLIN ALDECOA and JACK JUAN AVILA VELASQUEZ

Subjects
TOR serine-threonine kinases, Applied Mathematics, General Mathematics, Proteínas proto-oncogénicas c-akt, Neoplasms, Fosfatidilinositol 3-quinasa, Proto-oncogene proteins c-akt, Cáncer, Serina-treonina quinasas TOR, Phosphatidylinositol 3-kinase
Abstract

La vía PI3K/AKT/mTOR participa en múltiples procesos celulares fundamentales para la célula. Algunas mutaciones genéticas de los componentes de esta vía se han asociado a diversas enfermedades humanas: las más importantes son los carcinomas de mama, tiroides y endometrio, el glioblastoma multiforme, el cáncer de próstata y los linfomas. La vía canónica PI3K/AKT/mTOR se ha estudiado ampliamente en los últimos años. Sin embargo, el conocimiento de la complejidad de sus componentes principales y su interrelación con los elementos de otras vías va en aumento. Por ello, es importantes actualizar cada cierto tiempo la información disponible para la comprensión de este mecanismo. Así mismo, se están y se han desarrollado numerosos ensayos con medicinas selectivas en búsqueda de un tratamiento más inteligente para las enfermedades asociadas a alteraciones de esta vía. Por tanto, realizamos una revisión de esta vía de transducción con el objetivo de tener una visión cercana de su funcionamiento, sus alteraciones y enumerar algunas moléculas promisorias para ser utilizadas en futuros tratamientos. The PI3K/AKT/mTOR pathway is involved in multiple cellular processes which are essential for the cells. Some genetic mutations of the components of this pathway have been associated with various human diseases, the most important of which are breast, thyroid and endometrium carcinomas; glioblastoma multiforme; prostate cancer and lymphomas. The PI3K/AKT/mTOR canonical pathway has been extensively studied in recent years. However, as the complexity of its main components and their correlation with the components of other pathways are increasing, it is important to update from time to time the available information to understand this mechanism. Furthermore, many trials have been conducted with selective medicines aimed to look for a more intelligent treatment for diseases associated with alterations in this pathway. Therefore, we review this transduction pathway to take a close look at its functioning and alterations, and to list some promising molecules for future treatments. Revisión por pares

Published
2021

3. La vía canónica PI3K/AKT/mTOR y sus alteraciones en cáncer

Author

Aldecoa, F and Ávila, J

Subjects
TOR serine-threonine kinases, Proteínas proto-oncogénicas c-akt, Neoplasms, Fosfatidilinositol 3-quinasa, Proto-oncogene proteins c-akt, Cáncer, Serina-treonina quinasas TOR, Phosphatidylinositol 3-kinase
Abstract

The PI3K/AKT/mTOR pathway is involved in multiple cellular processes which are essential for the cells. Some genetic mutations of the components of this pathway have been associated with various human diseases, the most important of which are breast, thyroid and endometrium carcinomas; glioblastoma multiforme; prostate cancer and lymphomas. ThePI3K/AKT/mTOR canonical pathway has been extensively studied in recent years. However, as the complexity of its main components and their correlation with the components of other pathways are increasing, it is important to update fromtime to time the available information to understand this mechanism. Furthermore, many trials have been conducted with selective medicines aimed to look for a more intelligent treatment for diseases associated with alterations in this pathway. Therefore, we review this transduction pathway to take a close look at its functioning and alterations, and to list some promising molecules for future treatments. La vía PI3K/AKT/mTOR participa en múltiples procesos celulares fundamentales para la célula. Algunas mutaciones genéticas de los componentes de esta vía se han asociado a diversas enfermedades humanas: las más importantes son los carcinomas de mama, tiroides y endometrio, el glioblastoma multiforme, el cáncer de próstata y los linfomas. La vía canónica PI3K/AKT/mTOR se ha estudiado ampliamente en los últimos años. Sin embargo, el conocimiento de la complejidad de sus componentes principales y su interrelación con los elementos de otras vías va en aumento. Por ello, es importantes actualizar cada cierto tiempo la información disponible para la comprensión de este mecanismo. Así mismo, se están y se han desarrollado numerosos ensayos con medicinas selectivas en búsqueda de un tratamiento más inteligente para las enfermedades asociadas a alteraciones de esta vía. Por tanto, realizamos una revisión de esta vía de transducción con el objetivo de tener una visión cercana de su funcionamiento, sus alteraciones y enumerar algunas moléculas promisorias para ser utilizadas en futuros tratamientos.

Published
2021

4. Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)

Author

Laudina Rodríguez, Anika Hüsing, Isabelle Romieu, Rudolf Kaaks, Naomi E. Allen, Heiner Boeing, Federico Canzian, Carlotta Sacerdote, Kim Overvad, Núria Sala, David G. Cox, Elio Riboli, José María Huerta, Henk J. van Kranen, Lucie Dostal, H. Bas Bueno-de-Mesquita, Jane Nautrup Østergaard, Afshan Siddiq, Ruth C. Travis, María José Sánchez, Nerea Larrañaga, Anne Tjønneland, Angelika Stein, Göran Hallmans, Nicholas J. Wareham, Daniele Campa, Antonia Trichopoulou, Nina Roswall, Rosario Tumino, Pagona Lagiou, Mazda Jenab, Dimitrios Trichopoulos, Aurelio Barricarte, Mattias Johansson, Kay-Tee Khaw, Domenico Palli, Tobias Pischon, Sabina Sieri, [Campa, Daniele, Huesing, Anika, Stein, Angelika, Dostal, Lucie, Canzian, Federico, Kaaks, Rudolf] German Canc Res Ctr, Heidelberg, Germany. [Boeing, Heiner, Pischon, Tobias] Deutsch Inst Ernahrungsforsch, Dept Epidemiol, Potsdam, Germany. [Tjonneland, Anne, Roswall, Nina] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark. [Overvad, Kim, Ostergaard, Jane Nautrup] Aarhus Univ Hosp, Dept Cardiol, Cardiovasc Res Ctr, Aalborg Hosp, Aalborg, Denmark. [Overvad, Kim, Ostergaard, Jane Nautrup] Aarhus Univ, Dept Epidemiol, Sch Publ Hlth, DK-8000 Aarhus C, Denmark. [Rodriguez, Laudina] Hlth & Hlth Care Serv Council, Publ Hlth & Participat Directorate, Asturias, Spain. [Sala, Nuria] ICO IDIBELL, Barcelona, Spain. [Sanchez, Maria-Jose] Andalusian Sch Publ Hlth, Granada, Spain. [Sanchez, Maria-Jose, Larranaga, Nerea, Maria Huerta, Jose, Barricarte, Aurelio] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid, Spain. [Larranaga, Nerea] Basque Govt, Publ Hlth Dept Gipuzkoa, Gipuzkoa, Spain. [Maria Huerta, Jose] Murcia Reg Hlth Author, Dept Epidemiol, Murcia, Spain. [Barricarte, Aurelio] Navarre Publ Hlth Inst, Pamplona, Spain. [Khaw, Kay-Tee] Univ Cambridge, Sch Clin Med, Cambridge, England. [Wareham, Nicholas] MRC Epidemiol Unit, Cambridge, England. [Travis, Ruth C., Allen, Naomi E.] Univ Oxford, Nuffield Dept Clin Med, Canc Epidemiol Unit, Oxford, England. [Lagiou, Pagona, Trichopoulou, Antonia] Univ Athens, Sch Med, WHO Collaborating Ctr Food & Nutr Policies, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece. [Lagiou, Pagona, Trichopoulos, Dimitrios] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Trichopoulou, Antonia] Hellen Hlth Fdn, Athens, Greece. [Trichopoulos, Dimitrios] Acad Athens, Bur Epidemiol Res, Athens, Greece. [Palli, Domenico] Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy. [Sieri, Sabina] Fdn IRCCS Ist Nazl Tumori, Milan, Italy. [Tumino, Rosario] Civile MP Arezzo Hosp, Canc Registry, Ragusa, Italy. [Tumino, Rosario] Civile MP Arezzo Hosp, Histopathol Unit, Ragusa, Italy. [Sacerdote, Carlotta] Ctr Canc Prevent CPO Piemonte, Turin, Italy. [Sacerdote, Carlotta] Human Genet Fdn HuGeF, Turin, Italy. [van Kranen, Henk, Bueno-de-Mesquita, H. Bas] Natl Inst Publ Hlth & Environm, Ctr Nutr & Hlth CVG, Bilthoven, Netherlands. [Hallmans, Goran, Johansson, Mattias] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden. [Johansson, Mattias, Romieu, Isabelle, Jenab, Mazda] Int Agcy Res Canc, F-69372 Lyon, France. [Cox, David G., Siddiq, Afshan, Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, London, England. [Cox, David G.] Ctr Leon Berard, INSERM, F-69373 Lyon, France., Specific results of this study were obtained with financial support from the US Army Medical Research and Material Command (W81XWH-05-1-0156). http://cdmrp.army.mil/pcrp/default.shtml. The EPIC study was funded by 'Europe Against Cancer' Programme of the European Commission (SANCO), Ligue contre le Cancer (France), Société 3M (France), Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM), German Cancer Aid, German Cancer Research Center, German Federal Ministry of Education and Research, Danish Cancer Society, Health Research Fund (FIS) of the Spanish Ministry of Health, the participating regional governments and institutions of Spain, Cancer Research UK, Medical Research Council, UK, Hellenic Ministry of Health and Social Solidarity, the Stavros Niarchos Foundation and the Hellenic Health Foundation, Italian Association for Research on Cancer, Italian National Research Council, Dutch Ministry of Public Health, Welfare and Sports (VWS), Dutch Ministry of Health, Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) (The Netherlands), Statistics Netherlands, Swedish Cancer Society, Swedish Scientific Council, Regional Government of Skane, Sweden, Norwegian Cancer Society, Department of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), German Institute of Human Nutrition Potsdam-Rehbrücke, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Cancer Epidemiology Institute, Department of Cardiology, Aarhus University Hospital, Public Health and Participation Directorate, Health and Health Care Services Council, Catalan Institute of Oncology, Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública (CIBERESP), Los Centros de Investigación Biomédica en Red (CIBER), Granada Cancer Registry, Andalusian School of Public Health [Granada], Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), CIBER de Epidemiología y Salud Pública (CIBERESP), Murcia Regional Health Authority, Public Health Institute of Navarra, School of Clinical Medicine, University of Cambridge [UK] (CAM), Epidemiology Unit, Medical Research Council, Cancer Epidemiology Unit, University of Oxford [Oxford]-Cancer Epidemiology Unit, WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene-Epidemiology and Medical Statistics-Athens Medical School, Department of Hygiene, Epidemiology and Medical Statistics, Harvard School of Public Health, Bureau of Epidemiologic Research, Academy of Athens, Molecular and Nutritional Epidemiology Unit, ISPO-Cancer Research and Prevention Institute, Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Cancer Registry, Civile - M.P.Arezzo Hospital, CPO Piemonte, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Department of Public Health and Clinical Medicine/Nutritional Research, Umeå University, Nutrition and Metabolism Section, International Agency for Cancer Research (IACR), Unit of Nutrition, Environment, and Cancer, Equipe 6, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Genomics of Common Disease, Imperial College London-School of public health, The University of Hong Kong (HKU)-The University of Hong Kong (HKU), Department of Epidemiology and Biostatistics, Imperial College London-Faculty of Medicine-School of public health, Department of Epidemiology and Public Health, Imperial College London, Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Aalborg Hospital-Aarhus University Hospital, Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública ( CIBERESP ), Andalusian School of Public Health, University of Cambridge [UK] ( CAM ), Azienda Ospedaliera 'Civile M.P.Arezzo', National Institute for Public Health and the Environment [Bilthoven] ( RIVM ), University of Umeå, International Agency for Research on Cancer, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
Oncology, Male, MESH: Carcinoma, Epidemiology, protein p53, MESH : Aged, PROTEIN, Genome-wide association study, MESH : Genotype, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, KAPPA-B ACTIVATION, MESH: Genotype, 0302 clinical medicine, PKC-IOTA, Epidemiology of cancer, Multicenter Studies as Topic, TUBEROUS SCLEROSIS, MESH: Genetic Variation, lcsh:Science, MESH : Isoenzymes, 0303 health sciences, MESH: Middle Aged, MESH : Carcinoma, TOR Serine-Threonine Kinases, Cancer Risk Factors, target of rapamycin kinase, MTOR protein, MESH: Case-Control Studies, 3. Good health, 030220 oncology & carcinogenesis, Medicine, Science & Technology - Other Topics, MESH : Genome-Wide Association Study, Phenomena and Processes::Genetic Phenomena::Genetic Variation [Medical Subject Headings], MESH : Prostatic Neoplasms, Phenomena and Processes::Chemical Phenomena::Chemical Processes::Biochemical Processes::Signal Transduction [Medical Subject Headings], medicine.medical_specialty, MESH : Case-Control Studies, Genotype, Single-nucleotide polymorphism, Variación genética, 03 medical and health sciences, Genetics, Cancer Genetics, Humans, MESH : Middle Aged, human, Biology, mammalian target of rapamycin, Aged, Estudio Multicéntrico, Science & Technology, MESH: Humans, MULTIDISCIPLINARY SCIENCES, lcsh:R, MESH : Humans, Genetic Variation, medicine.disease, MESH : Neoplasms, Genitourinary Tract Tumors, Genetic epidemiology, Cardiovascular and Metabolic Diseases, Case-Control Studies, KINASE-C-IOTA, MESH: Genome-Wide Association Study, MESH: Multicenter Studies as Topic, lcsh:Q, MESH : Genetic Predisposition to Disease, RAPAMYCIN, Lifestyle Causes of Cancer, MESH: Signal Transduction, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Multicenter Studies as Topic [Medical Subject Headings], lcsh:Medicine, Bioinformatics, MESH : Multicenter Studies as Topic, Prostate cancer, Risk Factors, MESH: Risk Factors, Neoplasms, Clinical Epidemiology, MESH: Neoplasms, Protein Kinase C, MESH: Aged, Multidisciplinary, Prostate Cancer, MESH: Genetic Predisposition to Disease, Middle Aged, MESH : Risk Factors, European Prospective Investigation into Cancer and Nutrition, Europe, Isoenzymes, Diseases::Male Urogenital Diseases::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms [Medical Subject Headings], Genetic Epidemiology, protein kinase C lambda, MESH: Isoenzymes, MESH : TOR Serine-Threonine Kinases, isoenzyme, Cancer Epidemiology, Signal Transduction, Research Article, MESH : Male, Genetic Causes of Cancer, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, Neoplasias de la Próstata, Genetic polymorphisms, Serina-Treonina Quinasas TOR, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings], LUNG-CANCER, MESH : Genetic Variation, Internal medicine, medicine, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::TOR Serine-Threonine Kinases [Medical Subject Headings], Genetic Predisposition to Disease, MESH : Protein Kinase C, PI3K/AKT/mTOR pathway, Genetic Association Studies, MESH: TOR Serine-Threonine Kinases, 030304 developmental biology, MESH : Signal Transduction, COMPLEX, Càncer de pròstata, Polimorfisme genètic, Carcinoma, MTOR protein, human, protein kinase C, Cancer, Prostatic Neoplasms, Cancers and Neoplasms, Human Genetics, MESH: Protein Kinase C, MESH: Male, MAMMALIAN TARGET, MESH: Prostatic Neoplasms, CELL-GROWTH, MESH: Europe, EPIC, Genome-Wide Association Study
Abstract

International audience; The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR and p53 pathways. We investigated the genetic variability of 67 key genes in the mTOR pathway and in genes of the p53 pathway which interact with mTOR. We tested the association of 1,084 tagging SNPs with prostate cancer risk in a study of 815 prostate cancer cases and 1,266 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). We chose the SNPs (n = 11) with the strongest association with risk (p

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results